Cardiovascular Risk Reclassification Using Genetic Polymorphism Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for calculating cardiovascular risk are inadequate, particularly for individuals with intermediate risk and young people, as they fail to provide accurate predictions, leading to missed opportunities for preventive measures.
Innovation Solution
A method involving the determination of specific polymorphisms at positions 27 within nucleic acid sequences, combined with conventional risk factors, to reclassify cardiovascular risk and improve predictive accuracy, using a genetic score to identify individuals at higher risk of cardiovascular events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional risk factor-based methods are used for cardiovascular risk calculation, then the assessment is simple and widely applicable, but the predictive accuracy is insufficient particularly for individuals with intermediate risk and young people
Solution Approach 1:
The patent combines conventional risk factor assessment with genetic polymorphism analysis (specifically at positions 27 within nucleic acid sequences) to create an integrated cardiovascular risk assessment method. This merging of traditional clinical parameters with genetic information improves predictive accuracy while maintaining a structured assessment framework that builds upon existing conventional methods.
Solution Approach 2:
The patent introduces a genetic score as an intermediary element that bridges conventional risk factors and cardiovascular event prediction. The genetic score, derived from specific polymorphism determinations, serves as a mediator that enhances the predictive capability of the assessment system, particularly for individuals with intermediate risk profiles and young people where conventional methods fail.
2Reliability
If genetic polymorphism analysis is added to conventional risk factors, then the predictive accuracy improves, but the device complexity and cost increase
Solution Approach 1:
The patent segments the cardiovascular risk assessment into distinct components: conventional risk factor evaluation and genetic polymorphism analysis. This segmentation allows each component to be optimized independently, with the genetic analysis focused specifically on positions 27 within nucleic acid sequences, thereby managing complexity through structured division of the assessment process.
Solution Approach 2:
The patent changes the assessment parameters by incorporating specific genetic polymorphism data at positions 27 within nucleic acid sequences. This parameter addition transforms the risk assessment from purely clinical observations to a multi-dimensional evaluation that includes genetic susceptibility, thereby improving reliability without requiring complete reassessment of the entire evaluation framework.
3Measurement precision
If a genetic score is used to reclassify cardiovascular risk, then the identification of high-risk individuals improves, but the time and resources required for testing increase
Solution Approach 1:
The patent performs preliminary genetic polymorphism determination at positions 27 within nucleic acid sequences to establish a genetic score before final risk classification. This preliminary action allows for early identification of individuals with elevated genetic risk, enabling proactive risk stratification and preventing loss of time in later diagnostic stages by pre-establishing genetic susceptibility profiles.
Solution Approach 2:
The genetic score system serves multiple functions: it identifies high-risk individuals, stratifies risk categories, and guides preventive measure implementation. This multi-functionality reduces the need for separate testing protocols and streamlines the overall assessment process, thereby mitigating time loss despite the addition of genetic analysis.
Data Source
AI summary
The invention relates to a method for the reclassification of a subject to a more appropriate risk assessment to that obtained using the algorithms for such risk estimation such us but not limited to Framingham, Regicor, Score, Procam or Qrisk based on the presence of different polymorphisms. The invention also relates to a method for determining the risk of suffering a cardiovascular disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for CVD as well as computer-implemented methods for carrying out the risk determination.